Beiträge zum Schlagwort:

SoftSarcoma_ESMO

Neoadjuvant anthracycline plus ifosfamide shows survival advantage in high-risk soft tissue sarcoma

Neoadjuvant chemotherapy with an anthracycline plus ifosfamide showed significant survival gains in patients with soft tissue sarcoma (STS) of the trunk or extremities at high-risk of recurrence, compared to histologically-driven regimens.

Trabectedin demonstrated a significant increase in progression-free survival compared to best supportive care in advanced soft-tissue sarcoma

Results from the first trial to compare trabectedin to BSC for ASTS were presented at this year’s European Society for Medical Oncology Congress. Dr le Cesne, Medical Oncologist, Institut Gustave Roussy, France, showed results that provided further support for the use of trabectedin in ASTS.